Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIPNASDAQ:FDMTNASDAQ:HCATNASDAQ:OFIX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$66.98+1.4%$64.51$52.50▼$77.00$1.43B0.55312,546 shs215,811 shsFDMT4D Molecular Therapeutics$4.00+6.1%$3.64$2.24▼$28.93$174.64M2.84822,852 shs343,716 shsHCATHealth Catalyst$3.74-0.3%$3.92$3.49▼$9.24$260.66M1.53609,560 shs463,144 shsOFIXOrthofix Medical$10.97+1.6%$11.97$10.24▼$20.73$423.15M0.8282,641 shs254,143 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals+1.44%+5.73%+15.90%-0.28%+6.62%FDMT4D Molecular Therapeutics+6.10%-3.61%+14.61%+10.80%-82.80%HCATHealth Catalyst0.00%-1.84%+2.47%-17.44%-38.18%OFIXOrthofix Medical+1.57%+4.28%-1.17%-32.62%-15.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIPANI Pharmaceuticals3.6376 of 5 stars2.51.00.03.32.13.31.3FDMT4D Molecular Therapeutics1.9913 of 5 stars3.33.00.00.00.61.70.6HCATHealth Catalyst4.4323 of 5 stars4.32.00.03.80.92.51.3OFIXOrthofix Medical3.1214 of 5 stars3.52.00.00.02.03.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 3.00Buy$80.1319.63% UpsideFDMT4D Molecular Therapeutics 2.60Moderate Buy$29.56638.89% UpsideHCATHealth Catalyst 2.64Moderate Buy$8.00113.90% UpsideOFIXOrthofix Medical 3.00Buy$21.5095.99% UpsideCurrent Analyst Ratings BreakdownLatest HCAT, OFIX, FDMT, and ANIP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2025OFIXOrthofix MedicalBarrington ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$16.006/17/2025HCATHealth CatalystBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral6/11/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (D-)6/6/2025OFIXOrthofix MedicalJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform5/24/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)5/12/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.005/10/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)5/9/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $25.005/9/2025FDMT4D Molecular TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $44.005/9/2025FDMT4D Molecular TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$45.00 ➝ $38.005/8/2025HCATHealth CatalystCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $9.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$614.38M2.36$7.71 per share8.69$19.11 per share3.50FDMT4D Molecular Therapeutics$40K4,633.00N/AN/A$11.05 per share0.36HCATHealth Catalyst$306.58M0.85$0.35 per share10.62$6.00 per share0.62OFIXOrthofix Medical$799.49M0.54N/AN/A$13.07 per share0.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals-$18.52M-$1.27N/A15.91N/A-3.12%21.35%7.52%8/5/2025 (Estimated)FDMT4D Molecular Therapeutics-$160.87M-$3.18N/AN/AN/A-767,126.06%-33.26%-30.68%8/6/2025 (Estimated)HCATHealth Catalyst-$69.50M-$1.15N/AN/AN/A-23.34%-6.14%-2.74%8/6/2025 (Estimated)OFIXOrthofix Medical-$126M-$3.69N/AN/AN/A-17.78%-28.15%-16.51%8/5/2025 (Estimated)Latest HCAT, OFIX, FDMT, and ANIP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025ANIPANI Pharmaceuticals$1.37$1.70+$0.33$0.69$179.75 million$197.12 million5/8/2025Q1 2025FDMT4D Molecular Therapeutics-$0.84-$0.86-$0.02-$0.86$0.53 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/AFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/AHCATHealth CatalystN/AN/AN/AN/AN/AOFIXOrthofix MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.462.661.98FDMT4D Molecular TherapeuticsN/A12.3612.36HCATHealth Catalyst0.401.241.24OFIXOrthofix Medical0.382.711.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%FDMT4D Molecular Therapeutics99.27%HCATHealth Catalyst85.00%OFIXOrthofix Medical89.76%Insider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals12.70%FDMT4D Molecular Therapeutics9.60%HCATHealth Catalyst2.60%OFIXOrthofix Medical1.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60021.66 million18.91 millionOptionableFDMT4D Molecular Therapeutics12046.33 million41.88 millionOptionableHCATHealth Catalyst1,50069.60 million67.79 millionOptionableOFIXOrthofix Medical1,61639.18 million38.67 millionOptionableHCAT, OFIX, FDMT, and ANIP HeadlinesRecent News About These CompaniesBarrington Research Upgrades Orthofix Medical (NASDAQ:OFIX) to Strong-BuyJune 25 at 1:51 AM | americanbankingnews.comBarrington Research Initiates Coverage of Orthofix Medical (OFIX) with Outperform RecommendationJune 24 at 5:19 AM | msn.comOrthofix Medical Inc. (NASDAQ:OFIX) Insider Aviva Mcpherron Sells 3,728 SharesJune 24 at 4:53 AM | insidertrades.comInsider Selling: Orthofix Medical Inc. (NASDAQ:OFIX) Insider Sells 3,728 Shares of StockJune 23 at 5:47 PM | marketbeat.comOrthofix Medical Inc. (NASDAQ:OFIX) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 23 at 10:45 AM | marketbeat.comBarrington Research Begins Coverage on Orthofix Medical (NASDAQ:OFIX)June 23 at 9:05 AM | marketbeat.comOrthofix Shareholders Meeting and Board ElectionsJune 20, 2025 | tipranks.comAssenagon Asset Management S.A. Has $1.18 Million Stock Position in Orthofix Medical Inc. (NASDAQ:OFIX)June 18, 2025 | marketbeat.comOrthofix Announces Global Commercial Launch of the TrueLok Elevate Transverse Bone Transport SystemJune 17, 2025 | finance.yahoo.comOrthofix Medical (NASDAQ:OFIX) shareholders have endured a 67% loss from investing in the stock five years agoJune 17, 2025 | finance.yahoo.comOrthofix Medical Inc. (NASDAQ:OFIX) Short Interest Up 43.4% in MayJune 16, 2025 | marketbeat.comOrthofix Medical (NASDAQ:OFIX) Upgraded by Wall Street Zen to "Hold" RatingJune 15, 2025 | americanbankingnews.comWall Street Zen Upgrades Orthofix Medical (NASDAQ:OFIX) to "Hold"June 14, 2025 | marketbeat.comWall Street Zen Downgrades Orthofix Medical (NASDAQ:OFIX) to SellJune 7, 2025 | marketbeat.comOrthofix Medical's (OFIX) Market Perform Rating Reaffirmed at JMP SecuritiesJune 6, 2025 | marketbeat.comOrthofix Medical Inc. (NASDAQ:OFIX) Director Purchases $24,570.00 in StockJune 6, 2025 | insidertrades.comOrthofix Medical Inc. (NASDAQ:OFIX) Short Interest UpdateJune 6, 2025 | marketbeat.comOrthofix Reports Larger Than Expected Loss Per ShareJune 5, 2025 | ryortho.comOrthofix Medical Inc. (NASDAQ:OFIX) Director Alan Lee Bazaar Purchases 2,250 SharesJune 5, 2025 | marketbeat.comHighridge Medical sells EBI bone healing division to focus on spineJune 5, 2025 | massdevice.comAvista Healthcare Partners acquires Highridge Medical’s bone healing unit EBIJune 5, 2025 | pehub.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHCAT, OFIX, FDMT, and ANIP Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$66.98 +0.95 (+1.44%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$66.98 0.00 (0.00%) As of 06/24/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.4D Molecular Therapeutics NASDAQ:FDMT$4.00 +0.23 (+6.10%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$4.02 +0.02 (+0.52%) As of 04:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.Health Catalyst NASDAQ:HCAT$3.74 -0.01 (-0.27%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$3.74 +0.00 (+0.13%) As of 06/24/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases. It offers services expertise solutions comprising data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is headquartered in South Jordan, Utah.Orthofix Medical NASDAQ:OFIX$10.97 +0.17 (+1.57%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$10.66 -0.31 (-2.82%) As of 06/24/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations. The Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
